Guard Therapeutics International AB (publ)

OM:GUARD BTA Stock Report

Market Cap: SEK 323.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Guard Therapeutics International Management

Management criteria checks 1/4

Guard Therapeutics International's CEO is Tobias Agervald, appointed in Jan 2019, has a tenure of 5.75 years. directly owns 0.21% of the company’s shares, worth SEK673.76K. The average tenure of the management team and the board of directors is 4.1 years and 2.6 years respectively.

Key information

Tobias Agervald

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.8yrs
CEO ownership0.2%
Management average tenure4.1yrs
Board average tenure2.6yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Tobias Agervald's remuneration changed compared to Guard Therapeutics International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-SEK 79m

Mar 31 2024n/an/a

-SEK 88m

Dec 31 2023n/an/a

-SEK 113m

Sep 30 2023n/an/a

-SEK 137m

Jun 30 2023n/an/a

-SEK 146m

Mar 31 2023n/an/a

-SEK 134m

Dec 31 2022SEK 5mSEK 2m

-SEK 113m

Sep 30 2022n/an/a

-SEK 95m

Jun 30 2022n/an/a

-SEK 97m

Mar 31 2022n/an/a

-SEK 88m

Dec 31 2021SEK 4mSEK 2m

-SEK 82m

Sep 30 2021n/an/a

-SEK 69m

Jun 30 2021n/an/a

-SEK 47m

Mar 31 2021n/an/a

-SEK 44m

Dec 31 2020SEK 3mSEK 1m

-SEK 40m

Sep 30 2020n/an/a

-SEK 43m

Jun 30 2020n/an/a

-SEK 39m

Mar 31 2020n/an/a

-SEK 41m

Dec 31 2019SEK 4mSEK 1m

-SEK 45m

Compensation vs Market: Insufficient data to establish whether Tobias's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Tobias's compensation has increased whilst the company is unprofitable.

CEO

Tobias Agervald (48 yo)

5.8yrs

Tenure

SEK 5,230,000

Compensation

Mr. Tobias Larsson Agervald has been Chief Executive Officer at Guard Therapeutics International AB (publ) (formerly known as A1M Pharma AB (publ))since January 15, 2019 and served as its Chief Medical Off...

Leadership Team

NamePositionTenureCompensationOwnership
Tobias Agervald
Chief Executive Officer5.8yrsSEK 5.23m0.21%
SEK 673.8k
Karin Botha
Chief Financial Officer4.1yrsno data0.024%
SEK 76.3k
Magnus Gram
C.S.O5.3yrsno datano data
Peter Gilmour
Head of Preclinical Science4.2yrsno datano data
Sara Thuresson
Head of Clinical Operations3.4yrsno data0.016%
SEK 52.2k
Michael Reusch
Chief Medical Officer2.8yrsno datano data
Torbjorn Larsson
Head of Chemistry2.4yrsno data0.0017%
SEK 5.4k

4.1yrs

Average Tenure

51yo

Average Age

Experienced Management: GUARD BTA's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Johan Bygge
Independent Chairman of the board3.4yrsSEK 271.00k0.052%
SEK 168.5k
Khatereh Ahmadi
Non-Executive Directorless than a yearno datano data
Michael Brownstein
Member of Scientific Boardno datano datano data
Goran Forsberg
Non-Executive Independent Director5.4yrsSEK 162.00k0.011%
SEK 36.7k
Fredrik Lehmann
Non-Executive Independent Director1.8yrsSEK 7.00kno data
Gunvor Ordeberg
Member of Scientific Boardno datano datano data
Anthony Kettle
Member of Scientific Boardno datano datano data
Christopher Redman
Member of Scientific Boardno datano datano data
Henning Schneider
Member of Scientific Boardno datano datano data
Johannes Hulthe
Non-Executive Independent Director5.4yrsSEK 162.00k0.050%
SEK 160.8k
Hege Hellstrom
Non-Executive Directorless than a yearno datano data
József Balla
Member of Scientific Boardno datano datano data

2.6yrs

Average Tenure

59yo

Average Age

Experienced Board: GUARD BTA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/09 18:27
End of Day Share Price 2024/10/09 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guard Therapeutics International AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonCarnegie Commissioned Research
Lars HevrengDanske Bank
Hans MählerNordea Markets